Human parainfluenza virus type 3 hemagglutinin–neuraminidase protein (HPIV3 HN)

The human parainfluenza virus type 3 hemagglutinin–neuraminidase protein (HPIV3 HN) is a multifunctional envelope glycoprotein critical for viral infection and spread. It attaches the virus to host cell surface sialic acid-containing receptors (hemagglutinin activity), promotes membrane fusion by activating the F (fusion) protein, and facilitates the release of new virions by cleaving sialic acids from glycoproteins (neuraminidase activity). HPIV3 HN features distinct structural domains responsible for binding and enzymatic functions, and contains at least two receptor binding sites with different roles in viral attachment and fusion activation. It is a validated target for antiviral drug development; neuraminidase inhibitors such as zanamivir have demonstrated biochemical inhibition, though potent HN inhibitors must generally block both enzymatic and receptor-binding functions to fully impede viral entry and spread. Structural adaptation in HN, including at its dimer interface, can regulate its fusion promotion activity and contribute to viral fitness, presenting both challenges and opportunities for therapeutic targeting.

Other names

HPIV3 HNParainfluenza virus 3 hemagglutinin–neuraminidaseHemagglutinin-neuraminidase (in HPIV3 context)

Competitive inhibition of neuraminidase active site (drugs like zanamivir or sialic acid analogues bind to active site, blocking receptor cleavage) Receptor binding site blockade (potential mechanism for antiviral action is inhibition of hemagglutinin function by blocking sialic acid interaction)